Novo Nordisk to cap insulin prices in Minnesota settlement

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Minnesota AG Reaches Another Insulin Price Cap Settlement
Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a month.
Novo Nordisk insulin now $35 per month for Minnesotans thanks to Attorney General Keith Ellison
Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.
Novo Nordisk Caps Insulin Prices Following Minnesota Lawsuit Settlement
Novo Nordisk has agreed to a legal settlement capping insulin prices, following Minnesota's attorney general's accusations of price gouging. The settlement mandates a price cap of $35 per monthly prescription and provides free insulin to needy Minnesotans.
MN Novo Nordisk settlement over insulin pricing [RAW]
Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires Novo Nordisk to offer its insulin products to Minnesotans for no more than $35 a month over the next five years.
All Minnesotans can now get insulin for just $35 a month
ST. PAUL, Minn. – All Minnesotans, whether they have insurance or not, will be able to buy insulin products for $35 a month for the next five years.
Novo Norodisk caps insulin prices at $35 for Minnesotans
Now Novo Nordisk is required to provide insulin products at $35 per monthly prescription for customers paying with cash. The settlement also requires all three companies to use a texting system to raise awareness of low-cost insulin options, according to the press release.
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Settlement secures $35-per-month insulin for all Minnesotans
The final settlement has been reached in the state's 2018 lawsuit filed against the three largest insulin manufacturers.
FOX 9 Minneapolis-St. Paul on MSN3d
Minnesota insulin lawsuit: AG Ellison reaches settlement with Novo Nordisk
Minnesota Attorney General Keith Ellison is expected to announce a "major development" in the litigation against three large ...
Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU)
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...
Sanofi plans share buybacks, signals more deals post Opella sale
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...
Novo Nordisk's SWOT analysis: stock outlook amid GLP-1 market growth
A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...
BioPharma Dive55m
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...